Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
